Bowne & Co. adopts $35mln stock repurchase plan under Rule 10b5-1.

Bowne & Co. has adopted a stock repurchase plan under Rule 10b5-1 to buy up to $35 million of its common stock. The plan allows the company to purchase shares at times when it might be restricted from doing so due to insider trading laws or self-imposed trading blackout periods. The repurchase program was previously announced.

Bowne & Co. has adopted a stock repurchase plan under Rule 10b5-1 to buy up to $35 million of its common stock. The plan allows the company to purchase shares at times when it might be restricted from doing so due to insider trading laws or self-imposed trading blackout periods. The repurchase program was previously announced.

The plan, authorized by the company's Board of Directors, will enable Bowne & Co. to repurchase shares from the open market, through privately negotiated transactions, or by other means, as long as it complies with applicable securities laws. The timing, number, and value of shares repurchased will be determined by the company's management, taking into account market conditions and other corporate considerations.

Bowne & Co. has not provided specific details on the expected impact of the repurchase program on shareholder value. However, the company's decision to implement this plan suggests confidence in its current financial position and future prospects. The repurchase program may be modified, suspended, or terminated at any time at the company's discretion, without any obligation to acquire a specific amount of common stock.

About Bowne & Co.
Bowne & Co. is a leading provider of financial services and investment solutions. The company specializes in various investment areas, including equities, fixed income, and alternative investments. Bowne & Co. has a strong focus on research and development, continually seeking new opportunities to enhance its investment offerings and meet the evolving needs of its clients.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to a multitude of risks and uncertainties that could cause actual results to differ materially from those projected. You are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements in this release are made as of the date hereof, and the company undertakes no obligation to update such statements.

References:
[1] https://www.nasdaq.com/articles/biorestorative-therapies-inc-announces-2-million-stock-repurchase-program-enhance